ArticleUpdates in surgery2026
CT imaging is a feasible method for the preoperative prediction of the main pathologic response after neoadjuvant therapy for locally advanced esophageal squamous cell carcinoma.
Article in Updates in surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
The purpose of this study was to explore the feasibility of predicting the main pathologic response (MPR) after neoadjuvant therapy (NAT) for locally advanced esophageal squamous cell carcinoma (LAESCC) using computed tomography (CT) imaging. From January 2022 to December 2023, a retrospective study was conducted on 150 patients who underwent neoadjuvant therapy and radical resection of R0 esophageal cancer in our hospital. Before and after neoadjuvant therapy, the tumour volume (TV) was manually delineated using an enhanced CT image background processor combined with MIMINICS reconstruction software, and the tumour volume regression rate (TVRR) was calculated. Binary logistic regression was used to analyse the factors influencing the postoperative pathological MPR using univariate and multivariate analyses. Determine the predictive value of TVRR through the receiver operating characteristic curve. The mean baseline tumor volume regression ratio was 42.8% (± 22.0). Multivariate analysis revealed that the neoadjuvant therapy mode, tumour volume after neoadjuvant therapy (TV after NAT) and TVRR were independent factors affecting the postoperative pathological MPR. According to the receiver operating characteristic (ROC) analysis, the TVRR showed good predictive value for the postoperative pathological MPR (AUC = 0.828, sensitivity = 85.7%, specificity = 71.2%, p < 0.001), and the cut-off value determined by the Youden index was 42.61%. Subgroup analysis indicated that TVRR had good predictive efficacy for postoperative pathological MPR in different neoadjuvant treatment modes and various tumour locations in the thoracic segment. The TVRR before and after neoadjuvant therapy for esophageal squamous cell carcinoma is an independent factor influencing the postoperative pathological MPR and has good predictive efficacy.
Indexed as
Identifiers
41824274What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.